

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**March 5, 2026**

---

**I New Study - Initial Review**

**MM1MDS-CTG02**, A Phase II Study Of Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 MyeloMATCH Substudy (Version Date 01/20/26)

---

**II New Study - Initial Review**

**MM10A-S04**, A Randomized Phase II Trial of ASTX727 with Standard Duration versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A MyeloMATCH Substudy (Version Date 01/05/26)

---

**III Continuing Review**

**S1937**, A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy (Version Date 12/13/24)

---

**IV Continuing Review**

**S2101**, Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study (Version Date 07/23/25)

---

## **V Continuing Review**

**S2104**, Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (Version Date 07/08/24)

---

## **VI Continuing Review**

**S2212**, Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study (Version Date 04/18/25)

---

## **VII Continuing Review**

**S2213**, A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis (Version Date 01/23/26)

---

## **VIII Continuing Review**

**S2308**, Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma (Version Date 12/19/25)

---

## **IX Continuing Review**

**A031801**, A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCaL) (Version Date 08/01/25)

---

## **X Continuing Review**

**A032302**, Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE) (Version Date 07/09/25)

## **XI Continuing Review**

**A052101**, A Randomized Phase 3 Trial of Continuous vs Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON) (Version Date 09/24/24)

---

## **XII Continuing Review**

**A092001**, Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma (Version Date 07/03/25)

---

## **XIII Continuing Review**

**CCTG-HN11**, SPECT-CT Guided Elective Contralateral Neck Treatment (Select) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial (Version Date 08/22/22)

---

## **XIV Continuing Review**

**EA2234**, A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (Version Date 07/14/25)

---

## **XV Continuing Review**

**EAA181**, Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (Version Date 01/29/26)

---



## **XVI Continuing Review**

**NRG-GI008**, Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) (Version Date 05/20/25)

---

## **XVII Continuing Review**

**NRG-GI011**, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) (Version Date 12/09/25)

---

## **XVIII Continuing Review**

**E2905**, Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia (Version Date 08/12/22)

---